KDR and neoplasm: At present, target therapy options for ccRCC includes the tyrosine kinase inhibitors (TKI) like sunitinib [10], mTOR inhibitors like tesirolimus which can directly interfere with it by acting on mTOR, thereby inhibiting tumor cell proliferation, transformation, and tumor angiogenesis [11], monoclonal antibody like bevacizumab which binds to circulating VEGF to prevent it from activating VEGFR, so as to achieve the purpose of anti-tumor angiogenesis [12].